ECSP056186A - Composición farmacéutica en forma de hidrogel para administración transdérmica de sustancias activas - Google Patents

Composición farmacéutica en forma de hidrogel para administración transdérmica de sustancias activas

Info

Publication number
ECSP056186A
ECSP056186A EC2005006186A ECSP056186A ECSP056186A EC SP056186 A ECSP056186 A EC SP056186A EC 2005006186 A EC2005006186 A EC 2005006186A EC SP056186 A ECSP056186 A EC SP056186A EC SP056186 A ECSP056186 A EC SP056186A
Authority
EC
Ecuador
Prior art keywords
hydrogel
pharmaceutical composition
active substances
transdermal administration
relates
Prior art date
Application number
EC2005006186A
Other languages
English (en)
Inventor
Patrick Franke
Original Assignee
Schering Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=33395772&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ECSP056186(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Schering Ag filed Critical Schering Ag
Publication of ECSP056186A publication Critical patent/ECSP056186A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/265—Esters, e.g. nitroglycerine, selenocyanates of carbonic, thiocarbonic, or thiocarboxylic acids, e.g. thioacetic acid, xanthogenic acid, trithiocarbonic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/18—Feminine contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/06—Anabolic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/26—Androgens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones

Abstract

La invención se refiere a una composición farmacéutica en forma de hidrogel que comprende un diéster de ácido carboxílico, un alquilalcohol-C2-C4, una sustancia activa y una matriz de polímero. La invención se refiere también, al uso de un diéster de ácido carboxílico como intermediario de permeación transdérmica para una sustancia activa de una composición farmacéutica en forma de hidrogel, donde la composición comprende una matriz de polímero y un alquilalcohol-C2-C4. La invención se refiere igualmente a una composición resistente a la transpiración en forma de hidrogel que comprende un polímero de acrilo en combinación con un derivado de celulosa.
EC2005006186A 2003-04-28 2005-11-25 Composición farmacéutica en forma de hidrogel para administración transdérmica de sustancias activas ECSP056186A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP03008856 2003-04-28

Publications (1)

Publication Number Publication Date
ECSP056186A true ECSP056186A (es) 2006-04-19

Family

ID=33395772

Family Applications (1)

Application Number Title Priority Date Filing Date
EC2005006186A ECSP056186A (es) 2003-04-28 2005-11-25 Composición farmacéutica en forma de hidrogel para administración transdérmica de sustancias activas

Country Status (33)

Country Link
EP (2) EP1617827B1 (es)
JP (2) JP4829102B2 (es)
KR (1) KR101093999B1 (es)
CN (1) CN1780610B (es)
AR (1) AR044113A1 (es)
AT (2) ATE385786T1 (es)
AU (1) AU2004233572B2 (es)
BR (1) BRPI0409918A (es)
CA (1) CA2523734C (es)
CL (1) CL2004000884A1 (es)
CO (1) CO5640075A2 (es)
CR (1) CR8059A (es)
CY (1) CY1108069T1 (es)
DE (2) DE502004011164D1 (es)
DK (1) DK1617827T3 (es)
EA (1) EA008686B1 (es)
EC (1) ECSP056186A (es)
ES (2) ES2345458T3 (es)
HK (1) HK1087633A1 (es)
HR (1) HRP20080178T3 (es)
JO (1) JO2492B1 (es)
MX (1) MXPA05011541A (es)
NO (1) NO20055601L (es)
NZ (2) NZ543264A (es)
PE (1) PE20050461A1 (es)
PL (1) PL1617827T3 (es)
PT (1) PT1617827E (es)
RS (1) RS51307B (es)
SI (1) SI1617827T1 (es)
TW (1) TWI343259B (es)
UA (1) UA83036C2 (es)
WO (1) WO2004096191A1 (es)
ZA (1) ZA200509549B (es)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0506139D0 (en) * 2005-03-24 2005-05-04 Transphase Ltd A transdermal topical composition and its uses
GB0506141D0 (en) * 2005-03-24 2005-05-04 Transphase Ltd A topical compostion and its uses
DE102005015128B4 (de) * 2005-03-31 2008-12-11 Bayer Schering Pharma Aktiengesellschaft Wafer enthaltend Steroidhormone
DE102005035879A1 (de) * 2005-07-30 2007-02-01 Paul Hartmann Ag Hydrogel
SE536091C2 (sv) * 2011-04-14 2013-04-30 Pep Tonic Medical Ab Farmaceutisk komposition innehållande oxytocin eller fragment eller varianter därav och åtminstone en icke-jonisk cellulosaeter
JP5934781B2 (ja) * 2011-04-25 2016-06-15 パーク、ジュン−ヒョン 脱毛防止及び発毛促進用外用剤組成物
FR2976808B1 (fr) * 2011-06-22 2013-06-28 Urgo Lab Composition filmogene et son utilisation pour le traitement de l'herpes
US9855211B2 (en) * 2013-02-28 2018-01-02 Novan, Inc. Topical compositions and methods of using the same
DE102018213754A1 (de) * 2018-08-15 2020-02-20 Henkel Ag & Co. Kgaa "Tris(hydroxymethyl-)aminomethan oder seine Salze als Wirkstoff zur Reduzierung der Schweißsekretion“

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3341557A (en) 1961-06-05 1967-09-12 Upjohn Co 7-methyltestosterones
DE1182229B (de) 1960-11-16 1964-11-26 Upjohn Co Verfahren zur Herstellung von 7-Methylsteroiden
US3924004A (en) 1971-11-24 1975-12-02 Syntex Corp Fatty alcohol-propylene carbonate-glycol solvent cream vehicle
US4000273A (en) 1973-11-01 1976-12-28 Richardson-Merrell Inc. Method for the control of fertility
JPS5540604A (en) * 1978-09-14 1980-03-22 Mitsui Toatsu Chem Inc Improved local topicum
FR2518879A1 (fr) * 1981-12-30 1983-07-01 Besins Jean Medicament a base d'oestradiol pour le traitement de la pathologie menopausique
JPS5970612A (ja) 1982-10-13 1984-04-21 Nippon Redarii Kk ゲル軟膏基剤
ATE72129T1 (de) * 1987-05-27 1992-02-15 Burghart Kurt Transdermal therapeutisch wirkende pharmazeutische zubereitung sowie vorrichtung zum aufbringen der zubereitung.
DE58909570D1 (de) * 1988-10-27 1996-02-22 Schering Ag Mittel zur transdermalen applikation enthaltend gestoden
WO1993025168A1 (en) * 1992-06-11 1993-12-23 Theratech, Inc. The use of glycerin in moderating transdermal drug delivery
US5460620A (en) * 1992-07-31 1995-10-24 Creative Products Resource, Inc. Method of applying in-tandem applicator pads for transdermal delivery of a therapeutic agent
WO1996008255A1 (en) 1994-09-14 1996-03-21 Minnesota Mining And Manufacturing Company Transdermal device for delivery of levonorgestrel
FR2732223B1 (fr) 1995-03-30 1997-06-13 Sanofi Sa Composition pharmaceutique pour administration transdermique
DE19526864A1 (de) 1995-07-22 1997-01-23 Labtec Gmbh Hormonpflaster
JPH09194396A (ja) 1996-01-17 1997-07-29 Pola Chem Ind Inc 貼付剤用マトリックス
US5733565A (en) 1996-02-23 1998-03-31 The Population Council, Center For Biomedical Research Male contraceptive implant
KR970064620A (ko) * 1996-03-05 1997-10-13 임성기 사이클로스포린-함유 외용약제 조성물
US5736128A (en) * 1996-05-14 1998-04-07 Isp Investments Inc. Cosmetic composition for rejuvenation of skin without skin irritation
EP0954260A1 (en) 1996-05-22 1999-11-10 Diversified Pharmaceuticals, Inc. Compositions, methods and devices for the transdermal delivery of drugs
IT1283102B1 (it) * 1996-06-06 1998-04-07 Permatec Nv Composizione terapeutica per la somministrazione transdermica di un principio attivo estrogeno o progestinico o di loro miscele
US5993787A (en) 1996-09-13 1999-11-30 Johnson & Johnson Consumer Products, Inc. Composition base for topical therapeutic and cosmetic preparations
US20020012694A1 (en) 1997-09-17 2002-01-31 Alfred J. Moo-Young Transdermal administration of ment
US6767902B2 (en) 1997-09-17 2004-07-27 The Population Council, Inc. Androgen as a male contraceptive and non-contraceptive androgen replacement
HUP0102274A3 (en) 1998-06-19 2002-08-28 Akzo Nobel Nv Testosterone derivative and pharmaceutical compositions containing the same
FR2781666B1 (fr) * 1998-07-30 2000-09-08 Oreal Composition cosmetique solide et ses utilisations
JP2935113B1 (ja) * 1998-09-24 1999-08-16 小林製薬株式会社 インドメタシン経皮吸収剤
JP2000264899A (ja) * 1999-01-13 2000-09-26 Taisho Pharmaceut Co Ltd ステロイド外用剤
WO2000041702A1 (fr) 1999-01-13 2000-07-20 Taisho Pharmaceutical Co., Ltd. Preparation steroide externe
JP2001139451A (ja) * 1999-11-17 2001-05-22 Lion Corp ジェル状化粧料
EP1343804A1 (en) 2000-12-15 2003-09-17 Akzo Nobel N.V. 14(15)-unsaturated 15- and/or 16- substituted androgens with mixed androgen-progestational profile
DE10104327A1 (de) * 2001-01-24 2002-07-25 Schering Ag 11beta-Halogensteroide, deren Herstellung und Verwendung zur Herstellung von Arzneimitteln sowie 11beta-Halogensteroide enthaltende pharmazeutische Präparate
DE10107663B4 (de) 2001-02-19 2004-09-09 Lts Lohmann Therapie-Systeme Ag Testosteronhaltiges transdermales therapeutisches System, Verfahren zu seiner Herstellung und seine Verwendung

Also Published As

Publication number Publication date
HRP20080178T3 (en) 2008-05-31
UA83036C2 (ru) 2008-06-10
CY1108069T1 (el) 2014-02-12
EP1875905B1 (de) 2010-05-12
CN1780610A (zh) 2006-05-31
CL2004000884A1 (es) 2005-03-11
KR101093999B1 (ko) 2011-12-15
EP1875905A2 (de) 2008-01-09
DE502004006196D1 (de) 2008-03-27
CA2523734C (en) 2009-12-22
ATE385786T1 (de) 2008-03-15
JP4829102B2 (ja) 2011-12-07
WO2004096191A1 (de) 2004-11-11
PL1617827T3 (pl) 2008-07-31
EP1617827B1 (de) 2008-02-13
CO5640075A2 (es) 2006-05-31
SI1617827T1 (sl) 2008-06-30
RS51307B (sr) 2010-12-31
CA2523734A1 (en) 2004-11-11
ATE467412T1 (de) 2010-05-15
TWI343259B (en) 2011-06-11
AR044113A1 (es) 2005-08-24
NZ543264A (en) 2010-03-26
CR8059A (es) 2006-05-29
AU2004233572A1 (en) 2004-11-11
EA200501583A1 (ru) 2006-06-30
EP1875905A3 (de) 2008-06-25
NO20055601D0 (no) 2005-11-25
CN1780610B (zh) 2010-06-09
MXPA05011541A (es) 2006-05-31
RS20050809A (en) 2007-09-21
NZ583760A (en) 2011-10-28
EP1617827A1 (de) 2006-01-25
JP2006524653A (ja) 2006-11-02
TW200524644A (en) 2005-08-01
HK1087633A1 (en) 2006-10-20
PE20050461A1 (es) 2005-08-13
JO2492B1 (en) 2009-10-05
JP2010241824A (ja) 2010-10-28
BRPI0409918A (pt) 2006-04-25
EA008686B1 (ru) 2007-06-29
ES2300763T3 (es) 2008-06-16
DE502004011164D1 (de) 2010-06-24
ZA200509549B (en) 2007-02-28
PT1617827E (pt) 2008-04-30
NO20055601L (no) 2006-01-26
ES2345458T3 (es) 2010-09-23
AU2004233572B2 (en) 2010-07-15
DK1617827T3 (da) 2008-06-02
KR20060007403A (ko) 2006-01-24

Similar Documents

Publication Publication Date Title
ECSP056186A (es) Composición farmacéutica en forma de hidrogel para administración transdérmica de sustancias activas
CL2009000035A1 (es) Compuestos derivados 3-espiro-heterociclo-1il-5h-ciclopentan[d]pirimidin-indol, util para inhibir la actividad de akt quinasa; composicion farmaceutica que comprende dichos compuestos; y uso en el tratamiento de enfermedades tal como cancer, fibrosis quistica, diabetes, enfermedad de alzheimer, entre otras.
ES2534304T3 (es) Procedimientos y composiciones que implican miARN y moléculas inhibidoras de miARN
CL2011000935A1 (es) Composicion farmaceutica que comprende acetaminofeno y un material de tramadol complejo, que exhibe una liberacion sostenida y coordinada a traves de una capa de liberacion sostenida y otra de liberacion inmediata; metodo de preparacion;y el uso de un material complejo de tramadol y acetaminofeno para preparar un medicamento para el tratamiento del dolor.
BRPI0608297A2 (pt) composições de lipossomos
BR112013016772B8 (pt) compostos, uso do composto e composição farmacêutica
BRPI0915300C1 (pt) compostos de éster boronato e composições farmacêuticas dos mesmos
CL2009000541A1 (es) Uso de una enzima degradadora de matriz activable (amde) para la formulacion de un medicamento de administracion sub-epidermica; composicion farmacologica y su uso; combinacion que comprende a amde, un activador y un agente; recipiente para amde y para el activador; kit que comprende dicho recipiente
UY27486A1 (es) Queratinocitos utilizables como sustancia biológicamente activa en el tratamiento de heridas
UY31543A1 (es) Sistema de administracion de rnai de interferencia y usos del mismo
NI200500164A (es) Nueva difenilazetidinona con caracteristicas fisiologicas mejoradas, correspondiente metodo de produccion, medicamentos que contienen dicho compuesto y su uso.
EA201300121A1 (ru) Ингибитор дпп-4 в комбинации с дополнительным противодиабетическим агентом, таблетки, включающие указанные композиции, их применение и способ их получения
BRPI0516830A (pt) composições de droga de liberação sustentada convenientemente implantáveis
CR8428A (es) Agente endoparasiticidas para la administracion topica
CL2007001435A1 (es) Compuestos derivados de fenilalanina; proceso de prepatacion; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto como inhibidores de integrina para el tratamiento del cancer.
CY1108700T1 (el) Συνθεσεις απελευθερωσης φαρμακου εστερα αλφα-υδροξυ οξεος και μεθοδοι χρησης
CL2008000442A1 (es) Composicion farmaceutica que comprende a un quitosano, un ingrediente activo cosmetico o farmaceutico, y un solvente volatil; y su uso para tratar psoriasis, micosis entre otras enfermedades.
CL2010001406A1 (es) Composicion farmaceutica oftalmica que comprende povidona yodada, y un compuesto antiinflamatorio esteroidal, un compuesto antiinflamatorio no esteroidal, un antibacteriano, un antialergico o un compuesto antiglaucoma; y metodo para preservar la composicion.
AR051765A1 (es) Compuestos de moleculas conjugadas con una actividad reforzada de absorcion de celulas
ITPD20050207A1 (it) Nuove composizioni farmaceutiche contenenti acido ialuronico e collagenas nel trattamento topico di ferite, ustioni ed ulcere
CY1116111T1 (el) Τοπικη συνθεση για τη θεραπεια της ακτινικης κερατωσης
PA8586201A1 (es) Nuevas formulaciones de liberacion prolongada inyectables
AR048672A1 (es) Tabletas de desintegracion que comprenden licarbazepina
CL2009001841A1 (es) Uso de una composición de liberación sostenida de 4-aminopiridina para preparar un medicamento útil para tratar esclerosis multiple en un sujeto.
AR058047A1 (es) Administracion de inhibidores de dipeptidil peptidasa